دورية أكاديمية
Results Of Monotherapy And Combination Treatment Of Daratumumab In Relapsed Refractory Multiple Myeloma - Single Center Experience ; Relaps refrakter multiple myelomda daratumumabın tekli ve kombine tedavi sonuçları-tek merkez deneyimi
| العنوان: | Results Of Monotherapy And Combination Treatment Of Daratumumab In Relapsed Refractory Multiple Myeloma - Single Center Experience ; Relaps refrakter multiple myelomda daratumumabın tekli ve kombine tedavi sonuçları-tek merkez deneyimi |
|---|---|
| المؤلفون: | AKDENİZ, Aydan, AKBAŞ, Fatma, TOMBAK, Anıl |
| المصدر: | Volume: 8, Issue: 4 627-630 ; 2147-9607 ; Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi |
| بيانات النشر: | Celal Bayar Üniversitesi Celal Bayar University |
| سنة النشر: | 2021 |
| المجموعة: | DergiPark Akademik (E-Journals) |
| مصطلحات موضوعية: | Daratumumab,multiple myeloma,Survival., Multiple myelom,daratumumab,sağkalım |
| الوصف: | Objective: With the addition of proteasome inhibitors and immunomodulators to multiple myeloma treatment protocols in recent years, the response rates have improved considerably, but in relaps refractory patients treatment options are still limited and survival is short. Daratumumab is a human CD38 monoclonal antibody and has achieved a very good response in both monotherapy and combination therapies.Although it has been proven effective in clinical studies, the literature information of daratumumab obtained from real-life data, is very limited for our country. Therefore we aimed to examine the characteristics and response rates of patients who were treated with daratumumab in our center.Materials and Methods: Files of 10 patients treated with daratumumab, were analyzed retrospectively. Data containing demographics and response rates were evoluated in the light of literature.Results: Mean age at diagnosis of patients was 58 years. Median follow-up time was 58.3 months and median duration of daratumumab treatment was 3.9 months. The median overall response rate was 40%. All patients with at least partial response were taking the Dara-Bor-Dex combination. Totally 60% of patients were alive. Median time from daratumumab to death was 35 days.Conclusion: In our study, similar with the literature, response rates were improved with daratumumab in the treatment of relapsed refractory myeloma ; Giriş ve Amaç: Son yıllarda multipl miyelom tedavi protokollerine proteazom inhibitörleri ve immünomodülatörlerin eklenmesiyle, yanıt oranları önemli ölçüde iyileşmiştir, ancak relaps refrakter hastalarda tedavi seçenekleri hala sınırlıdır ve sağkalım kısadır. Daratumumab, bir insan CD38 monoklonal antikorudur ve hem monoterapi ile hem de kombinasyon terapilerinde çok iyi bir yanıt elde etmiştir.Klinik çalışmalarda etkinliği kanıtlanmış olmasına rağmen, daratumumabın gerçek yaşam verilerinden elde edilen literatür bilgileri ülkemizde oldukça sınırlıdır. Bu nedenle merkezimizde daratumumab ile tedavi edilen hastaların karakteristik ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Turkish |
| العلاقة: | https://dergipark.org.tr/tr/download/article-file/1600689Test; https://dergipark.org.tr/tr/pub/cbusbed/issue/67602/886457Test |
| DOI: | 10.34087/cbusbed.886457 |
| الإتاحة: | https://doi.org/10.34087/cbusbed.886457Test https://dergipark.org.tr/tr/pub/cbusbed/issue/67602/886457Test |
| رقم الانضمام: | edsbas.585BF336 |
| قاعدة البيانات: | BASE |
| DOI: | 10.34087/cbusbed.886457 |
|---|